COVID-19

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

5 months ago

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional…

5 months ago

Silo Wellness Announces Extension of Kaya/NUGL LOI; Annual Filings Delay

Springfield, Oregon--(Newsfile Corp. - February 27, 2024) - Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("Silo" or "the…

5 months ago

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

5 months ago

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions…

5 months ago

Validic integrates Smart Meter cellular-enabled health devices into personalized care platform

DURHAM, N.C., Feb. 26, 2024 /PRNewswire/ -- Validic Inc., a market-leading digital health and personalized care company, continues to expand…

5 months ago

MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies

LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Today MAX BioPharma, Inc. (www.maxbiopharma.com) and Metaba, LLC (www.metaba.us) announced their collaboration in…

5 months ago

CLS Holdings USA Inc. (“CLSH”) Announces Repayment of $1,526,250 in Principal and Interest Debenture Obligations Along with the Repurchase of 13,274,780 Shares of the Company

LAS VEGAS, NV / ACCESSWIRE / February 26, 2024 / CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), the ''Company'' or ''CLS'', a…

5 months ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose…

5 months ago

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year…

5 months ago